Project Grant R21AI190606
- The federal Project Grant award titled "Understanding Plasmodium Vivax Transmission Networks Through a Novel Microhaplotype and Kinship Analysis Approach" was provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) for $437,625 from August 1, 2025 to July 31, 2027. The award supports research to assess the effectiveness of reactive case detection (RCD) as a malaria control intervention by using high-resolution...
- This $406,450 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to establish continuous in vitro culture and genetic engineering capabilities for the Plasmodium vivax malaria parasite. The project aims to mimic the physiological conditions of P. vivax infection by optimizing reticulocyte production and culture conditions in a bespoke bioreactor. This will enable fundamental studies...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $267,168 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Institut Pasteur DU Cambodge, a non-profit research establishment in Phnom Penh, Cambodia. The grant aims to leverage access to Plasmodium vivax (P. vivax) parasite diversity to identify culture-adaptable strains and develop robust in vitro culture systems. This would enable advanced studies on P. vivax malaria, which poses...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) totaling $549,032 is funding research to develop a safe, effective, and cost-effective multistage malaria vaccine based on a biopolymer particle platform technology. The objective is to design biopolymer particles that can simultaneously display epitopes or antigen subdomains from various malaria parasite stages to induce broad immune responses and...
- The federal Project Grant award of $385,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Iowa State University to characterize proteases involved in the replication of the Plasmodium apicoplast genome, which is crucial for the survival of the malaria parasite. The research aims to confirm the localization of three candidate proteases within the apicoplast, assess their importance for parasite growth...
- This $230,808 project grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research by Washington University in St. Louis to investigate heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum. The project aims to identify parasite heme-binding proteins and assess their essentiality for parasite viability, as well as examine the role of the heme...
- This $244,440 federal Project Grant was awarded on January 14, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant was awarded to the Albert Einstein College of Medicine in Bronx, New York to conduct research on the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against the liver stage of malaria infection. The research seeks to gain insights into the cellular immune...
- This $412,581 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research on specialized mitochondrial DNA polymerases in African trypanosomes - parasites that cause neglected tropical diseases such as human African trypanosomiasis, Chagas disease, and leishmaniasis. The project aims to clarify the roles of two trypanosome-specific DNA polymerases (POLIB and POLID) in maintaining the parasite's...
- This $426,250 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the function of two peroxisome-derived proteins, PEX4 and PEX22, in apicomplexan parasites like Plasmodium falciparum and Toxoplasma gondii. These parasites cause major infectious diseases such as malaria and toxoplasmosis. The research aims to improve understanding of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $192,364 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Yale University on August 4, 2025. The project aims to investigate the impact of antimalarial drugs on parasite development and drug resistance selection within mosquito vectors. The research combines controlled lab studies of mosquito and parasite strains, as well as analysis of field samples from Burkina Faso and Senegal,...
This $190,261 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a longitudinal cohort study of Plasmodium vivax (PV) malaria relapses in Central Africa. The study aims to determine the proportion of PV infections with relapses, the periodicity of relapses, the genetic diversity of relapse parasites compared to primary infections, and the impact of relapse infections on malaria transmission. This research will address critical knowledge gaps around the epidemiology and transmission dynamics of PV malaria, which is an understudied public health challenge in Africa despite growing evidence of its prevalence. Drexel University, the awardee, will conduct this research over a period from August 2025 to July 2027 to inform strategies for controlling and eliminating vivax malaria in the region.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $50.0k | 9/3/25 | ||
| Not listed | $140.3k | 8/25/25 |